Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Stock Information for ENDRA Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.